Project Grant R01CA310024
Award Date 7/22/26
Completion Date 6/30/31
Dollars Obligated $690K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Durham, NC 27710, USA
Similar Awards
- The National Cancer Institute awarded Duke University $626,475 under the Cancer Biology Research program (CFDA 93.396) on June 15, 2026, to investigate how integrin alpha-6 drives metabolic adaptation and breast cancer survival in leptomeningeal metastasis. The research examines the molecular mechanisms by which integrin alpha-6, a laminin receptor, enables breast cancer cells to migrate from bone marrow to the leptomeninges (the cerebrospinal fluid-containing membranes surrounding the brain and...
- The National Cancer Institute of the Department of Health and Human Services awarded The University of Kentucky Research Foundation $499,316 on September 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to characterize the role and regulation of HIVEP2 in tumor immune evasion in triple-negative breast cancer. The research investigates how HIVEP2, a zinc finger protein, drives immune evasion by promoting expression of interleukin-four induced gene 1 (IL4I1) and programmed cell...
- The National Cancer Institute, a component of the Department of Health and Human Services National Institutes of Health, awarded $637,509 to the University of California, San Diego on May 11, 2026, under the Cancer Biology Research program (CFDA 93.396, R01CA305983) to investigate GIV (GA-interacting vesicle-associated protein) as a master regulator of cancer cell signaling autonomy. The research examines how cancer cells sustain growth in nutrient- and growth factor-limited environments through...
- The National Cancer Institute awarded The Trustees of Columbia University in the City of New York $448,017 on August 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate prolactin signaling in brain metastasis of HER2-positive breast cancer. The research uses immunocompetent mouse models to elucidate mechanisms enabling HER2-positive breast cancer cells to colonize and thrive in the brain. The work has identified a tumor-pituitary-prolactin axis that drives...
- The National Cancer Institute, a division of the National Institutes of Health under the Department of Health and Human Services, awarded $134,000 to the University of Massachusetts Medical School on September 3, 2026, under the Cancer Biology Research program (CFDA 93.396). The recipient will conduct research employing genetically engineered mouse models to elucidate mechanisms by which loss of CAMK2B (calcium/calmodulin-dependent protein kinase II beta) promotes metastasis and immune...
- The National Cancer Institute awarded Duke University $1.882 million under the Cancer Biology Research program (CFDA 93.396) on September 23, 2025, to integrate genome-wide association study data with single-cell omics to reveal the cellular effectors of glioblastoma predisposition. Work will be performed in Durham, North Carolina, with a completion date of August 31, 2029. The Cancer Biology Research program funds fundamental information on the cause and nature of cancer, encompassing cancer...
- The National Cancer Institute, National Institutes of Health, awarded Sloan-Kettering Institute For Cancer Research $715,002 on April 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop HER2 positron emission tomography imaging methods for assessing HER2 heterogeneity and predicting response to HER2-targeted therapies in biliary tract cancer. The project addresses treatment resistance in metastatic biliary tract cancer by using molecular imaging to...
- The National Cancer Institute awarded Emory University $602,847 on July 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate the N-glycan modification pathway as a therapeutic target for triple-negative breast cancer, particularly in BRCA1-deficient patients. The project examines the role of MAN1C1, a glycosyl hydrolase, in breast cancer progression, immune evasion, and therapeutic resistance. The research addresses a critical gap: approximately 50–70 percent of...
- The National Cancer Institute awarded Duke University $402,135 on May 1, 2026, to develop SCHICAR, a single-cell tri-modal platform that simultaneously captures high-resolution three-dimensional genome interactions (including enhancer-promoter loops), chromatin accessibility, and transcriptomes from individual cells in cancer research. Duke's work addresses a critical limitation in existing single-cell three-dimensional genome methods, which suffer from poor efficiency in capturing long-range...
- The National Institute of Allergy and Infectious Diseases awarded Duke University $242,250 on June 22, 2026, to investigate how regulatory T cells suppress anti-breast cancer immunity and to identify molecular targets for therapeutic intervention under the Allergy and Infectious Diseases Research program (CFDA 93.855). The research focuses on strawberry notch homologs and their role in regulatory T cell-mediated suppression of anti-tumor immune responses. The project team identified a previously...